WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562693
CAS#: 1164153-22-3
Description: SR-3576 is a potent JNK3 inhibitor that is highly selective over p38.
Hodoodo Cat#: H562693
Name: SR-3576
CAS#: 1164153-22-3
Chemical Formula: C27H27N5O5
Exact Mass: 501.20
Molecular Weight: 501.540
Elemental Analysis: C, 64.66; H, 5.43; N, 13.96; O, 15.95
Synonym: SR-3576; SR 3576; SR3576;
IUPAC/Chemical Name: 3-[4-(3-m-Tolyl-ureido)-pyrazol-1-yl]-N-(3,4,5-trimethoxy-phenyl)-benzamide
InChi Key: MTFAYLZZDJGFGV-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H27N5O5/c1-17-7-5-9-19(11-17)30-27(34)31-21-15-28-32(16-21)22-10-6-8-18(12-22)26(33)29-20-13-23(35-2)25(37-4)24(14-20)36-3/h5-16H,1-4H3,(H,29,33)(H2,30,31,34)
SMILES Code: O=C(NC1=CC(OC)=C(OC)C(OC)=C1)C2=CC=CC(N3N=CC(NC(NC4=CC=CC(C)=C4)=O)=C3)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 501.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Kamenecka T, Habel J, Duckett D, Chen W, Ling YY, Frackowiak B, Jiang R, Shin Y, Song X, LoGrasso P. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. J Biol Chem. 2009 May 8;284(19):12853-61. doi: 10.1074/jbc.M809430200. Epub 2009 Mar 4. PubMed PMID: 19261605; PubMed Central PMCID: PMC2676016.